Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

Blood (2017) 129 (5): 572–581.

https://doi.org/10.1182/blood-2016-07-726588

Published: 2017

Includes: Supplemental data

Journal Articles

Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Nicholas J. Short, Elias Jabbour, Koji Sasaki, Keyur Patel, Susan M. O’Brien, Jorge E. Cortes, Rebecca Garris, Ghayas C. Issa, Guillermo Garcia-Manero, Rajyalakshmi Luthra, Deborah Thomas, Hagop Kantarjian, Farhad Ravandi

Blood (2016) 128 (4): 504–507.

https://doi.org/10.1182/blood-2016-03-707562

Published: 2016

Includes: Supplemental data

Journal Articles

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

Nitin Jain, Audrey V. Lamb, Susan O’Brien, Farhad Ravandi, Marina Konopleva, Elias Jabbour, Zhuang Zuo, Jeffrey Jorgensen, Pei Lin, Sherry Pierce, Deborah Thomas, Michael Rytting, Gautam Borthakur, Tapan Kadia, Jorge Cortes, Hagop M. Kantarjian, Joseph D. Khoury

Blood (2016) 127 (15): 1863–1869.

https://doi.org/10.1182/blood-2015-08-661702

Published: 2016

Includes: Supplemental data

Journal Articles

Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab

Yogin B Patel, PharmD, Hagop M. Kantarjian, MD, Deborah Thomas, MD, Susan O'Brien, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, Marina Konopleva, MD PhD, Nitin Jain, MD, Rebecca Garris, Jane Autry, RN, Elias Jabbour

Blood (2015) 126 (23): 2530.

https://doi.org/10.1182/blood.V126.23.2530.2530

Published: 2015

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Madeleine Duvic, MD, Joseph D Khoury, MD, Keyur Patel, MD, Naval Daver, MD, Susan O'Brien, MD, Sherry Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Elias Jabbour, Nitin Jain, MD, Stefan Faderl, MD, Deborah Thomas, MD, Arthur E. Frankel, MD, Muzaffar H. Qazilbash, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 3746.

https://doi.org/10.1182/blood.V126.23.3746.3746

Published: 2015

Journal Articles

Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience

Preetesh Jain, MD, DM, PhD, Hagop M Kantarjian, MD, Jorge E. Cortes, MD, Elias J. Jabbour, MD, Stefan H. Faderl, MD, William G. Wierda, MD, PhD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, MD, Srdan Verstovsek, MD, PhD, Jan A. Burger, MD, PhD, Luis Fayad, MD, Jorge Romaguera, MD, Rebecca Garris, BSc, Farhad Ravandi, MD, Susan O'Brien, MD, Deborah Thomas, MD

Blood (2013) 122 (21): 3917.

https://doi.org/10.1182/blood.V122.21.3917.3917

Published: 2013

Journal Articles

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Ohad Benjamini, MD, Hagop M Kantarjian, MD, Susan O'Brien, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Preetesh Jain, MD, DM, PhD, Sherry Pierce, Gautam Borthakur, MBBS, Tapan M. Kadia, MD, Elias Jabbour, MD, Zeev Estrov, MD, Rajyalakshmi Luthra, Ph.D., Jorge E. Cortes, MD

Blood (2013) 122 (21): 2734.

https://doi.org/10.1182/blood.V122.21.2734.2734

Published: 2013

Journal Articles

Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour, MD, Kantarjian Hagop, MD, Deborah Thomas, MD, Guillermo Garcia-Manero, MD, Daniela Hoehn, MD, PhD, Rebecca Garris, BSc, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD

Blood (2013) 122 (21): 2664.

https://doi.org/10.1182/blood.V122.21.2664.2664

Published: 2013

Journal Articles

Incidence and Outcome In Adults With Acute Lymphoblastic Leukemia With Primary Central Nervous System Involvement

Muhamed Baljevic, MD, Hagop M Kantarjian, MD, Deborah Thomas, MD, Michael Rytting, MD, Jyothsna Dasarathula, MBBS, Gautam Borthakur, MD, Jan A. Burger, MD, PhD, Farhad Ravandi, MD, Elias Jabbour, MD, Marina Konopleva, MD, PhD, Sherry Pierce, Mark Brandt, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2639.

https://doi.org/10.1182/blood.V122.21.2639.2639

Published: 2013

Journal Articles

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Naveen Pemmaraju, M.D., Deborah Thomas, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, John T Manning, MD, L. Jeffrey Medeiros, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Aziz Nazha, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Stefan Faderl, MD

Blood (2012) 120 (21): 3554.

https://doi.org/10.1182/blood.V120.21.3554.3554

Published: 2012

Journal Articles

Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

Stefan KÖhrer, MD, Greg Coffey, PhD, Ekaterina Kim, MS, Nathalie Y Rosin, PhD, Uma Sinha, PhD, Anjali Pandey, PhD, Medhat Shehata, Ulrich Jäger, Susan M. O'Brien, MD, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Deborah Thomas, MD, Hagop M Kantarjian, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 3532.

https://doi.org/10.1182/blood.V120.21.3532.3532

Published: 2012

Journal Articles

A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Tapan M. Kadia, MD, Jorge E. Cortes, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Alfonso Quintás-Cardama, MD, Melanie Baccus, RN, Rebecca Garris, BSc, Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2012) 120 (21): 4308.

https://doi.org/10.1182/blood.V120.21.4308.4308

Published: 2012

Journal Articles

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Farhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, Sherry Pierce, Stefan Faderl, Alessandra Ferrajoli, Charles Koller, Pramoda Challagundla, Sergernne York, Mark Brandt, Rajyalakshmi Luthra, Jan Burger, Deborah Thomas, Michael Keating, Hagop Kantarjian

Blood (2011) 118 (14): 3818–3823.

https://doi.org/10.1182/blood-2011-04-351502

Published: 2011

Journal Articles

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

Elias Jabbour, Deborah Thomas, Hagop Kantarjian, Lingsha Zhou, Sherry Pierce, Jorge Cortes, Srdan Verstovsek

Blood (2011) 118 (4): 899–902.

https://doi.org/10.1182/blood-2010-12-325589

Published: 2011

Journal Articles

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph + ) acute lymphoblastic leukemia

Farhad Ravandi, Susan O'Brien, Deborah Thomas, Stefan Faderl, Dan Jones, Rebecca Garris, Samuel Dara, Jeffrey Jorgensen, Partow Kebriaei, Richard Champlin, Gautam Borthakur, Jan Burger, Alessandra Ferrajoli, Guillermo Garcia-Manero, William Wierda, Jorge Cortes, Hagop Kantarjian

Blood (2010) 116 (12): 2070–2077.

https://doi.org/10.1182/blood-2009-12-261586

Published: 2010

Journal Articles

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

Guillermo Garcia-Manero, MD, Francesco Paolo Tambaro, MD, PhD, B. Nebiyou Bekele, PhD, Elias Jabbour, MD, Farhad Ravandi, M.D., Hui Yang, MD, PhD, Gautam Borthakur, MD, Tapan Kadia, MD, Jorge Cortes, MD, Stefan Faderl, MD, Marina Konopleva, MD, PhD, Sherry Pierce, RN, Jan A. Burger, MD, PhD, Zeev Estrov, MD, Susan O'Brien, M.D., Deborah Thomas, Willie Newsome, RN, Hagop Kantarjian, MD

Blood (2009) 114 (22): 1055.

https://doi.org/10.1182/blood.V114.22.1055.1055

Published: 2009

Journal Articles

Comparison of Thalidomide and Lenalidomide for the Treatment of Patients (pts) with Myelofibrosis (MF).

Elias Jabbour, MD, Hagop Kantarjian, MD, Sameer A Parikh, MD, Deborah Thomas, MD, Tapan Kadia, MD, Guillermo Garcia Manero, MD, Gautam Borthakur, MD, Sherry Pierce, RN, Mark Brandt, Jorge Cortes, MD, Srdan Verstovsek, MD, PhD

Blood (2009) 114 (22): 2901.

https://doi.org/10.1182/blood.V114.22.2901.2901

Published: 2009

Journal Articles

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

Wei-gang Tong, MD, PhD, Tapan Kadia, MD, Gautam Borthakur, MD, Elias Jabbour, MD, Sherry Pierce, RN, Jianqin Shan, PhD, Jorge Cortes-Franco, MD, Farhad Ravandi, MD, William Wierda, MD, PhD, Deborah Thomas, MD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2009) 114 (22): 3819.

https://doi.org/10.1182/blood.V114.22.3819.3819

Published: 2009

Journal Articles

A Phase 1 Study of Dose-Dense 5-Aza-2′-Deoxycitidine (decitabine) in Relapse Refractory Acute Lymphocytic Leukemia (ALL).

Guillermo Garcia-Manero, MD, Deborah Thomas, Michael Rytting, M.D., Patrick A. Zweidler-McKay, MD/PhD, Hui Yang, MD, PhD, Zhihong Fang, Shaoqing Kuang, PhD, Samuel Dara, Susan O'Brien, M.D., Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 2030.

https://doi.org/10.1182/blood.V114.22.2030.2030

Published: 2009

Journal Articles

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

Alfonso Quintás-Cardama, Hagop Kantarjian, Dan Jones, Jianqin Shan, Gautam Borthakur, Deborah Thomas, Steven Kornblau, Susan O'Brien, Jorge Cortes

Blood (2009) 113 (25): 6315–6321.

https://doi.org/10.1182/blood-2008-07-166694

Published: 2009

NARROW

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes

Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

Incidence and Outcome In Adults With Acute Lymphoblastic Leukemia With Primary Central Nervous System Involvement

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph + ) acute lymphoblastic leukemia

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

Comparison of Thalidomide and Lenalidomide for the Treatment of Patients (pts) with Myelofibrosis (MF).

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

A Phase 1 Study of Dose-Dense 5-Aza-2′-Deoxycitidine (decitabine) in Relapse Refractory Acute Lymphocytic Leukemia (ALL).

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only